BlackRock Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

BlackRock Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.33M	Buy	287,051 +2,461	+0.9%	+$34.8K	﹤0.01%	1197
2016 Q3	$4.34M	Sell	284,590 -973,320	-77%	-$39.4M	﹤0.01%	1169
2016 Q2	$48.8M	Sell	1,257,910 -12,062	-0.9%	-$433K	0.05%	302
2016 Q1	$35.3M	Buy	1,269,972 +70,929	+6%	+$2.36M	0.04%	388
2015 Q4	$64.5M	Buy	1,199,043 +19,938	+2%	+$1.01M	0.07%	273
2015 Q3	$47.2M	Buy	1,179,105 +468,445	+66%	+$15.3M	0.05%	308
2015 Q2	$22.7M	Sell	710,660 -422,410	-37%	-$10.7M	0.02%	484
2015 Q1	$27.1M	Buy	1,133,070 +161,830	+17%	+$3.62M	0.03%	462
2014 Q4	$17.1M	Sell	971,240 -3,925	-0.4%	-$61.3K	0.02%	603
2014 Q3	$13.4M	Sell	975,165 -91,369	-9%	-$1.37M	0.01%	695
2014 Q2	$18M	Buy	1,066,534 +5,387	+0.5%	+$89K	0.02%	599
2014 Q1	$19.3M	Buy	+1,061,147	New	+$19.2M	0.02%	564

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors's ITCI Position: Q4 2016 in Review

BlackRock Advisors increased its Intra-Cellular Therapies Inc. (ITCI) stake by 0.86% in Q4 2016, buying an estimated $34.8K and bringing the position to 287,051 shares worth $4.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1197.

BlackRock Advisors first reported a position in ITCI in Q1 2014 and has held it in 12 quarters since. The position peaked at $64.5M in Q4 2015. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

BlackRock Advisors held 287,051 shares of Intra-Cellular Therapies Inc. worth $4.33M as of Q4 2016.
BlackRock Advisors bought 2,461 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $34.8K.
Intra-Cellular Therapies Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1197 holding.
BlackRock Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Advisors's Intra-Cellular Therapies Inc. position peaked at $64.5M in Q4 2015.
129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.